Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

NCT06369259 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: Defactinib
DRUG: Cetuximab
DRUG: Avutometinib

Sponsor

M.D. Anderson Cancer Center